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Diagnostic utility of oxidative damage markers for early rheumatoid 
arthritis in non-smokers and negative anti-ccP patients
Utilidad diagnóstica de los marcadores de estrés oxidativo en artritis 
reumatoide precoz en pacientes no fumadores y anti-CCP negativos
e. Melguizo1, v. navarro2,3, b. Hernández2, K. santos1, t. arrobas1,4 c. Domínguez2, 
F. navarro2, c. gonzález1.
resuMen
Fundamento. A pesar del desarrollo de nuevos marcadores y cri-
terios diagnósticos para la artritis reumatoide (AR), todavía mu-
chos pacientes son diagnosticados tras varios años de síntomas. 
Los marcadores de estrés oxidativo se incrementan ya en una 
fase temprana de la enfermedad. El objetivo del presente estudio 
fue evaluar el valor diagnóstico adicional de estos marcadores.
Método. Se realizó un estudio de casos y controles. Los pacien-
tes reclutados para el estudio cumplían los criterios para AR de 
la ACR 1987, todos ellos tenían menos de 2 años de síntomas y 
sin tratamiento previo con fármacos modificadores de la enfer-
medad antirreumática (DMARD), esteroides o vitamina E. Los 
controles fueron seleccionados de los familiares del paciente 
y pareados (1:1) por sexo, edad, hábito tabáquico actual. Los 
marcadores de daño oxidativo que se midieron fueron malo-
nildialdehído (MDA), hidroperóxidos lipídicos (LOOH) y pro-
teínas carboniladas (CP). El Análisis estadístico se realizó de 
acuerdo con la STARD.
resultados. Se incluyeron sesenta y cinco pacientes con AR sin 
tratamiento y 65 controles sanos. LOOH, CP, los anticuerpos 
con péctidos citrulinados (anti-CCP) y el factor reumatoide 
(FR) fueron significativamente mayores en los pacientes, y 
MDA fue mayor en los controles. Los mismos resultados se 
obtuvieron en los subgrupos de pacientes que fuman o no, y 
en anti-CCP positivos o negativos. El valor diagnóstico de los 
marcadores tradicionales mostró una buena especificidad pero 
una baja sensibilidad. La construcción de los modelos logísti-
cos con la adicción de LOOH y CP aumenta la sensibilidad y 
el área bajo la curva ROC, especialmente en los no fumadores 
(66%) y los pacientes negativos ante-CCP (51%).
conclusiones. Al incorporar LOOH o CP a los marcadores de 
la enfermedad tradicionales en AR, bien por separado o ambos 
conjuntamente, mejoró el diagnóstico de AR, especialmente en 
los pacientes no fumadores o aquellos con anticuerpos anti-
CCP negativos.
Palabras clave. Sensibilidad. Hidroperóxido lipídico. Proteína 
carbonilada. Tabaco. Artritis reumatoide.
abstract
background. Besides the development of new markers and di-
agnostic criteria for rheumatoid arthritis (RA), many patients 
are still diagnosed after several years of symptoms. Oxidative 
stress markers are already increased at an early stage of RA. 
Our aim was to evaluate the additional diagnostic value of 
these markers.
Methods. A case-control study was performed. Patients met 
the 1987 RA ACR criteria, less than 2 years of symptoms and 
no previous treatment with disease-modifying anti-rheumatic 
drugs (DMARD), steroids or vitamin E. Controls were select-
ed from patient’s relatives and matched (1:1) by gender, age, 
and current smoking habit. Oxidative damage markers were 
malonyldialdehyde (MDA), Lipid hydroperoxides (LOOH) and 
Carbonyl proteins (CP). Statistical analysis was performed in 
agreement with the STARD initiative.
results. Sixty-five RA patients without treatment and 65 
healthy controls were included. LOOH, CP, antibodies against 
citrullinated peptides (anti-CCP) and rheumatoid factor (RF) 
were significantly higher in patients, and MDA higher in con-
trols. The same results were obtained in the subgroups of pa-
tients who smoke or not, and in anti-CCP positive or negative. 
The diagnosis performance of traditional markers showed 
good specificity but low sensitivity. The addition of LOOH and 
CP increased the sensitivity and the area under the receiving 
operating characteristic (ROC) curve especially in non-smok-
ing (66%) and negative anti-CCP (51%) patients.
conclusions. The separate or combined addition of LOOH 
or CP to the traditional disease markers improved the diag-
nosis of RA, especially in non-smoking or negative anti-CCP 
patients.
Key words. Sensitivity. Lipid hydroperoxide. Carbonyl protein. 
Smoking. Rheumatoid arthritis.
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introDuction
Despite the development of new spe-
cific markers and diagnostic criteria1, 
there is still an unacceptable delay in the 
diagnosis of RA, related to permanent 
disability. Moreover, smoking is the most 
important environmental factor involved 
in RA pathogenesis2,3 and a source of free 
radicals4, causing oxidative stress which is 
defined as the imbalance between the ox-
idative and anti-oxidative pathways of the 
body. Furthermore, it has been shown that 
oxidative stress is related with the emer-
gence and development of RA5,6 and it may 
act even before the onset of the disease7,8. 
Therefore, our hypothesis is that oxidative 
damage markers could be useful to diag-
nose RA patients in an early stage.
The aim of this study was to assess the 
additional diagnostic value of oxidative 
damage markers in diagnosing RA com-
bined with the traditional biochemical 
markers in patients with recent-onset RA. 
Secondly, we compared the accuracy of 
oxidative damage markers based on the 
smoking habit and the presence or absence 
of anti-CCP.
Material anD MetHoDs
Patients and samples
A case-control study was performed 
(January 2009 – February 2011), according 
to the local regulations and the Declaration 
of Helsinki. Written informed consent was 
obtained before the inclusion from every 
enrolled subject. Individuals included in this 
study were selected from the Early Arthri-
tis Office at the Rheumatology Department. 
RA patients met 1987 ACR criteria, had less 
than 2 years of symptoms and had not previ-
ously been treated with vitamin E, DMARDs 
or steroids. Controls were non-blood rela-
tives’ of the patients without chronic or in-
flammatory disease, matched 1:1 by gender, 
age (± 4 years), and current smoking habit.
Demographic characteristics, smok-
ing habit, disease related variables (in 
patients) and blood samples (into hepa-
rinized and non-heparinized tubes) were 
collected at one visit in all individuals. 
Samples were centrifuged in the next 30 
minutes at 2000xg and 4 ºC for 20 min, ob-
taining serum and plasma. An antioxidant 
cocktail (10% volume) was added to plas-
ma, and samples were stored at -80 ºC until 
analysis.
assays
MDA plasma levels (μM) were deter-
mined by high performance liquid chro-
matography (Chromsystem Instrument & 
Chemical Gmbh Heimbrugstrasse, Munich, 
Germany). Proteins were precipitated, a 
chromogen was added to the supernatant, 
detecting the resulting compound by an 
ultraviolet detector. The intra and inter-as-
say coefficient of variation (CV) were 4.7% 
and 8.5%, respectively.
LOOH were extracted from plasma us-
ing chloroform, reacted with ferrous ions, 
and the resulting ferric ions were quanti-
fied (μM), using thiocianate, by spectro-
photometry. The intra and inter-assay CV 
were <5% and 10%, respectively.
CP levels (μM) were determined using 
2,4-dinitrophenyl-hydrazine (DNPH) as a 
result of the difference in absorbance at 
365 nm between DNPH-treated samples 
and HCl-treated controls, with ε370=22.000 
M−1cm−1. The intra and inter-assay CV 
were 4.7% and 8.5%, respectively (Cayman 
Chemical Company, Ann Arbor, USA. Lipid 
hydroperoxide (LPO) and Carbonyl Protein 
assay kit).
Serum samples were used to perform 
traditional RA biomarkers: RF (IU/mL, intra 
and inter-assay CV were <3.4% and <3.5%, 
respectively) and C-reactive protein (CRP) 
(mg/L, intra and inter-assay CV were <5.2% 
and <5.1%, respectively) by inmunoturbidi-
metry (Bayer HealthCare, New York, USA). 
Anti-CCP (IU, intra and inter-assay CV were 
<8.0% and <7.0% respectively) 3rd genera-
tion were performed by ELISA (INOVA Diag-
nostics, Inc., San Diego, USA).
statistical methods
For descriptive purpose, median and 
interquartile range (IQR) in case of normal-
ity or mean and standard deviation (SD) in 
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case of non-normality for continuous vari-
ables were used. Relative percent frequen-
cies were used for categorical variables. 
The Wilcoxon matched-pairs signed-ranks 
and the McNemar tests were used to com-
pare continuous and dichotomous vari-
ables between case and control groups, 
respectively. Binary logistic regression 
models were used for the analysis in which 
RA diagnosis was the dependent variable 
and the traditional- and oxidative stress 
markers were included as independent 
variables. Sensitivity and specificity were 
calculated using ROC curves. This analy-
sis was performed in agreement with the 
STARD initiative9. Statistical analysis was 
performed using the STATA package v-10 
and SPSS v-19.
results
Sixty five DMARD and glucocorticoids 
naive RA patients and 65 healthy controls 
were included in the study. Patients were 
statistically significant different to controls 
in age, oxidative stress biomarkers, smok-
ing-dose (pack/years) and RA related vari-
ables. No statistical significant differences 
between patients and controls were found 
regarding gender and smoking habit (never, 
ever or current) (Table 1). These results are 
the same whether patients are divided into 
subgroups with respect to smoking or an-
ti-CCP antibodies positive or negative when 
compared with the healthy control group 
(Table 1). No significant differences in the 
classic markers of RA among patients ac-
cording to sex were found (data not shown).
table 1. Socio-demographic characteristics and serum levels of biormakers
Parameters
ra
patients
(n=65)
Median (iQr)
ra smoker 
patients
(n=22)
Median (iQr)
ra non-smokers 
patients
(n=43)
Median (iQr)
ra anti-ccP 
positive patients
(n=34)
Median (iQr)
ra anti ccP 
negative patients
(n=31)
Median (iQr)
Healthy
controls
(n=65)
Median (iQr)
Age (years) 50 (43-63)* 50 (43-56) 49 (43-64) 50 (43-63)* 50 (43-64)* 50 (41-60)
CRP (mg/L) 9.2 (3.4-25.4)* 8.9 (4.0-14.0)* 7.6 (2.2-31.3)* 8.9 (4.8-14.8)* 7.3 (1.1-29.5)* 1.0 (0.4-4.6)
LOOH (μM) 36.2 (26.7-51.2)* 37.4 (28.7-45.3)* 36.2 (23.6-52.7)* 35.3 (22.9-52.1)* 39.7 (27.3-51.2)* 16.7 (8.4-29.2)
CP (μM) 112.2 (59.1-147.0)* 106.2 (52.8-141.5)* 114.5 (62.8-150.8)* 108.7 (49.7-147.0)* 114.5 (65.8-150.8)* 46.0 (25.1-68.2)
MDA (μM) 8.0 (6.7-8.6)* 7.4 (6.7-8.5)* 8.1 (6.7-9.0)* 8.1 (6.7-8.4)* 7.7 (6.8-9.7)* 9.1 (8.5-10.1)
n (%) n (%) n (%) n (%) n (%) n (%)
Gender (female) 51 (79) 15 (68) 36 (84) 26 (76) 25 (81) 51 (79)
Smoking habit
Never 30 (46) 0 (0) 30 (70) 14 (41) 16 (52) 35 (54)
Ever 13 (20) 0 (0) 13 (30) 6 (18) 7 (22) 7 (11)
Current 22 (34) 22 (100) 0 (0) 14 (41) 8 (26) 23 (35)
Smoking dose
(pack year)
≤20
>20
44 (68)*
21 (32)*
7 (22)*
15 (68) 37 (86)*6 (14)
21 (62)*
13 (38)
8 (26)*
23 (74)
60 (92)
5 (8)
Shared epitope
Positive
Negative
34 (52)*
31 (48)
13 (59)*
9 (21)
20 (46)*
23 (54)
17 (50)*
17 (50)
16 (52)*
15 (48)
20 (31)
45 (69)
Anti-CCP 
(positive) 33 (51)* 14 (64)* 20 (46)* 34 (100)* 0 (100) 0 (0)
RF (positive) 41 (63)* 16 (73)* 25 (58)* 27 (79)* 14 (45)* 4 (7)
RA= rheumatoid arthritis, CRP= C-reactive protein, LOOH= lipid hydroperoxides, CP= carbonyl protein, MDA= malonyl-
dialdehyde, Anti-CCP= anti-cyclic citrullinated peptide, RF= rheumatoid factor.
*statistically significant differences (p<0.01) compared to the control group.
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Mean ± SD for disease variables in pa-
tients were as follows: symptoms duration 
9.0 ± 4.6 months; number of tender and 
swollen joints 10.7 ± 7.4 and 8.8 ± 1.2, re-
spectively; patients´ visual analogue scale 
(VAS) of RA 57.7 ± 25.2 mm; physician´ VAS 
of RA inflammation 50.8 ± 22.9 mm; dis-
ease activity score of four variables with 
C-reactive protein (DAS28_CRP) 4.8 ± 1.5; 
Health Assessment Questionnaire (HAQ) 
1.4 ± 0.8.
Diagnostics performance of different 
variables and logistic regression models 
for diagnostic of RA are shown in table 2. 
The shared epitope showed significant 
differences between patients and controls 
(table 1), but did not provide diagnostic 
utility. Due to the contradictory results of 
MDA, this was not used to build logistic re-
gression models. As expected, the diagno-
sis performance of traditional markers (RF, 
anti-CCP, CRP) showed good specificity but 
relatively low sensitivity. The addition of 
LOOH and CP (in lower grade) increased 
the sensitivity.
Furthermore, this sensitivity improve-
ment was higher in the subgroup of RA 
patients with negative anti-CCP (n= 31), 
in which the addition of LOOH and CP 
to classical biomarkers substantially im-
proved diagnostic performance. Similar 
results were found in the subgroup of 
non-smokers RA patients (n=43). Finally, 
traditional RA serological markers were 
more useful in smokers than non-smokers 
(AUC 0.966 (0.922-1.000) vs. 0.878 (0.803-
0.954), p=0.048). In the subgroup of smok-
ers, sensitivity, specificity and area under 
the ROC curve did not increase when 
markers of oxidative damage were added 
to the model (Table 2).
Discussion
In this study, we assessed the addi-
tional diagnostic value of oxidative stress 
markers for diagnosing patients with RA, 
in addition to avoiding the influence of 
the treatment have been selected patients 
who have no DMARD, glucocorticoid or 
antioxidant treatment. The classical mark-
ers showed the expected diagnosis per-
formance for a sample of patients with 
early RA1, where the addition of anti-CCP 
has not led to significant improvements 
in sensitivity10,11. As previously reported, 
both LOOH12 and CP13 were elevated in RA 
patients. Separately, LOOH and CP had 
better sensitivity but much lower specific-
ity than traditional biomarkers. Due to the 
contradictory results of MDA14, was not 
used to build logistic regression models 
because it showed no diagnostic accuracy 
and also showed very low area under the 
roc curve (Table 2). When the three clas-
sical markers and oxidative damage bio-
markers were added into the same model, 
diagnostic accuracy in recent-onset RA 
patients increased, especially due to sen-
sitivity raise. The best performance of the 
oxidative stress markers was for LOOH 
while CP marginally improved the accura-
cy of classical model, but not that already 
includes LOOH. A similar but reinforced 
behavior of oxidative damage biomarkers 
was observed in case of negative anti-CCP 
and non-smoking habit.
Thus, good sensitivity and specificity 
was observed when using together tra-
ditional markers and LOOH, especially 
in negative anti-CCP or non-smokers pa-
tients. Based on our initial hypothesis, 
these results show that oxidative damage 
markers can help to early diagnosis of RA 
when sensitivity is required or anti-CCP 
antibodies are negative. Other studies re-
ported results in the same way but they 
only focused on sensitivity and specifici-
ty and included patients with DMARD or 
steroids which have an antioxidant effect 
or were not in an early stage of the dis-
ease15. The most important strengths of 
our study are that all patients had not re-
ceived any antioxidant treatment and had 
a recent onset of the disease.
Furthermore, due to the observed ef-
fect in non-smokers, it appears that oxida-
tive stress contributes to the development 
of the disease as an independent factor of 
tobacco consumption. This result is con-
sistent with our previous work14 in which 
we reported an interaction between to-
bacco and oxidative stress with an in-
crease risk of RA development. Moreover, 
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table 2. RA Diagnostic performance and logistic models in total population, anti-CCP negative RA pa-
tients and non-smokers patients vs. controls
Parameter or model cut-off s (%) sp (%) lH+ lH- auc (95% ci) P
total 
population
RF 20.0 UI/mL 64.6 87.7 5.25 0.40 0.802 (0.722 – 0.881)
anti-CCP 20.0 IU 52.3 98.5 34.00 0.48 0.780 (0.700 – 0.860)
CRP 5.0 mg/L 67.7 78.5 3.14 0.41 0.808 (0.734 – 0.881)
LOOH 29.3 μM 69.2 78.5 3.21 0.39 0.758 (0.675 – 0.829)
CP 58.0 μM 76.9 70.8 2.63 0.33 0.791 (0.711 – 0.858)
MDA 8.5 μM 30.8 24.6 0.41 2.81 0.236 (0.150 – 0.322)
RF+anti-CCP+CRP 78.5 92.3 10.20 0.23 0.908 (0.855 – 0.962) reference
RF+anti-CCP+CRP+LOOH 86.2 93.8 14.01 0.15 0.951 (0.917 – 0.985) 0.035*
RF+anti-CCP+CRP+CP 81.5 93.8 13.26 0.20 0.934 (0.893 – 0.974) 0.082
RF+anti-CCP+CRP+LOOH+CP 86.2 93.8 14.01 0.15 0.959 (0.928 – 0.990) 0.020*
anti-ccP 
negative
patients
RF 20.0 UI/mL 48.4 87.7 3.93 0.59 0.730 (0.614 – 0.845)
CRP 5.0 mg/L 61.3 76.9 1.99 0.52 0.774 (0.668 – 0.880)
LOOH 22.5 μM 87.1 64.6 2.46 0.20 0.771 (0.689 – 0.839)
CP 52.8 μM 96.8 63.1 2.62 0.05 0.836 (0.761 – 0.895)
RF+CRP 54.8 93.8 8.83 0.48 0.820 (0.717 – 0.923) reference
RF+CRP+LOOH 71.0 93.8 11.45 0.31 0.903 (0.834 – 0.972) 0.049*
RF+CRP+CP 64.5 92.3 8.38 0.38 0.884 (0.814 – 0.954) 0.061
RF+CRP+LOOH+CP 71.0 92.3 9.22 0.31 0.918 (0.854 – 0.982) 0.022*
non-smokers 
patients
RF 20.0 UI/mL 60.5 87.7 4.91 0.45 0.752 (0.646 – 0.858)
anti-CCP 20.0 IU 46.5 98.5 30.23 0.54 0.728 (0.625 – 0.831)
CRP 5.0 mg/L 72.1 67.9 2.23 0.41 0.795 (0.709 – 0.881)
LOOH 22.5 μM 81.4 79.8 4.03 0.23 0.783 (0.697 – 0.854)
CP 52.4 μM 88.4 69.1 2.86 0.17 0.855 (0.777 – 0.913)
RF+anti-CCP+CRP 69.8 96.9 22.52 0.31 0.878 (0.803 – 0.954) reference
RF+anti-CCP+CRP+LOOH 76.7 93.9 12.57 0.25 0.934 (0.885 – 0.982) 0.05*
RF+anti-CCP+CRP+CP 74.4 98.5 49.60 0.26 0.911 (0.856 – 0.967) 0.10
RF+anti-CCP+CRP+LOOH+CP 79.1 93.8 12.75 0.22 0.948 (0.906 – 0.990) 0.02*
smokers 
patients
RF 20.0 UI/mL 77.3 91.3 8,885 0,24 0.927 (0.849 – 1.000)
anti-CCP 20.0 IU 68.2 91.3 7,839 0,34 0.907 (0.806 – 1.000)
CRP 5.0 mg/L 54.6 82.6 3,137 0,54 0.808 (0.678 – 0.939)
LOOH 22.5 μM 59.1 69.6 1,944 0,58 0.700 (0.542 – 0.857)
CP 52.4 μM 59.1 73.9 2,264 0,55 0.677 (0.516 – 0.837)
RF+anti-CCP+CRP 90.9 95.6 20,66 0,10 0,972 (0,933 – 1,000) reference
RF+anti-CCP+CRP+LOOH 90.9 95.6 20,66 0,10 0,984 (0,955 – 1,000) 0,411
RF+anti-CCP+CRP+CP 90.9 95.6 20,65 0,10 0,984 (0,959 – 1,000) 0,370
RF+anti-CCP+CRP+LOOH+CP 95.4 100.0 - 0,05 0,988 (0,963 – 1,000) 0,337
RF rheumatoid factor, anti-CCP anti cyclic citrullinated peptide antibodies, CRP C reactive protein, LOOH lipid hy-
droperoxides, CP carbonyl protein, S Sensibility, Sp Specificity, LH likelihood ratio, AUC area under ROC curve, CI 
confidence interval, *P value for AUC compared to the reference model in each group.
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recent studies associated smoking to the 
emergence of anti-CCP16, but not RF17, in 
patients with a specific HLA-DR (shared 
epitope) background, suggesting an etiol-
ogy role of tobacco restricted to this risk 
genetic factor18. In our group, there are sig-
nificant differences in the shared epitope 
but showed no diagnostic utility. In our 
patients, the addition of LOOH and CP 
to classical biomarkers increased signif-
icantly diagnostic accuracy in non-smok-
ers while provide no useful information in 
smokers. These results appear to reflect 
the association between anti-CCP and 
smoking in the disease.
The results of this study are limited by 
relative small sample size, because of the 
difficulty to recruit patients without previ-
ously DMARD or glucocorticoid treatment. 
However control sample is representative 
of the population actually at risk of having 
the disease, not of the general population 
because of study design19. Another limita-
tion of the study is the lack of standardiza-
tion of methods of measurement of various 
markers, although the methods were the 
same for patients and controls.
In conclusion, this study evaluated the 
diagnosis performance of oxidative dam-
age markers (LOOH and CP) in early RA 
patients. The separately or combined addi-
tion of these two oxidative damage mark-
ers to the traditional disease markers (RF, 
Anti-CCP, CRP) improved the diagnosis of 
RA, especially in the cases that sensitivity 
is required in order to discard the disease 
in negative anti-CCP patients or non-smok-
ers. Therefore, although the results of this 
study provide new evidence for including 
oxidative damage markers, LOOH and CP, 
as new tools to be included in the diagnos-
tic process or early RA, further studies with 
larger numbers of individuals are needed 
to confirm them.
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